We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

61 hedge funds and large institutions have $9.95M invested in ImmunityBio in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more call options, than puts

Call options by funds: $48K | Put options by funds: $38K

22% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 18

0% more funds holding

Funds holding: 61 → 61 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

2.76% less ownership

Funds ownership: 13.59% → 10.83% (-2.8%)

75% less capital invested

Capital invested by funds: $39.8M → $9.95M (-$29.9M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
61
Holders Change
–
Holders Change %
0%
% of All Funds
1.36%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
11
Increased
22
Reduced
18
Closed
11
Calls
$48K
Puts
$38K
Net Calls
+$10K
Net Calls Change
+$10K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$862K
2
CS
Candriam SCA
Luxembourg
+$532K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$319K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$309K
5
HK
Horizon Kinetics
New York
+$273K

Top Sellers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
-$9.85M
2
BlackRock
BlackRock
New York
-$1.87M
3
ProShare Advisors
ProShare Advisors
Maryland
-$132K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$111K
5
PPA
Parametric Portfolio Associates
Washington
-$101K
Name Holding Trade Value Shares
Change 		Change in
Stake
JG
26
Jefferies Group
New York
$49K +$95.8K +41,881 New
SG Americas Securities
27
SG Americas Securities
New York
$49K +$96.3K +42,111 New
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$44K +$21.9K +9,570 +33%
PP
29
Paloma Partners
Connecticut
$43K +$85.3K +37,271 New
OAM
30
Oxford Asset Management
United Kingdom
$40K +$79.1K +34,590 New
OC
31
Oppenheimer & Co
New York
$38K -$4.58K -2,000 -6%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$35K +$68.5K +29,933 New
Bank of America
33
Bank of America
North Carolina
$34K -$8.84K -3,862 -11%
State of Wisconsin Investment Board
34
State of Wisconsin Investment Board
Wisconsin
$34K +$27.7K +12,100 +71%
Citadel Advisors
35
Citadel Advisors
Florida
$31K -$3.21K -1,402 -5%
DekaBank Deutsche Girozentrale
36
DekaBank Deutsche Girozentrale
Germany
$29K -$13.7K -6,000 -18%
UBS Group
37
UBS Group
Switzerland
$28K +$38.9K +17,004 +243%
Wells Fargo
38
Wells Fargo
California
$25K -$11.2K -4,907 -19%
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$23K – – –
AIG
40
American International Group
New York
$22K -$327 -143 -0.8%
HF
41
HRT Financial
New York
$19K +$39K +17,042 New
Citigroup
42
Citigroup
New York
$17K +$18.8K +8,216 +142%
VOYA Investment Management
43
VOYA Investment Management
Georgia
$16K – – –
Simplex Trading
44
Simplex Trading
Illinois
$16K +$31.9K +13,958 +21,809%
FAAS
45
First Allied Advisory Services
California
$14K +$4.58K +2,000 +19%
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$13K -$1.44K -629 -5%
EWM
47
Edge Wealth Management
New York
$12K +$22.9K +10,000 New
Macquarie Group
48
Macquarie Group
Australia
$7K +$11.2K +4,900 +544%
Legal & General Group
49
Legal & General Group
United Kingdom
$5K – – –
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$3.24K +$4.08K +1,783 +176%
1
2
3

IBRX Hedge Fund Activity: Q4 2018 in Review

61 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2018, worth a combined $9.95M — down 75% from $39.8M a quarter earlier.

Fund positioning in IBRX was balanced in Q4 2018: 11 funds opened new positions, 11 closed out, 22 added to existing stakes and 18 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $862K. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $9.85M sold.

  • 61 institutional investors held ImmunityBio (IBRX) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $9.95M of ImmunityBio stock for Q4 2018, down 75% quarter-over-quarter.
  • 11 funds opened new ImmunityBio positions in Q4 2018 and 11 closed out, a net change of 0 holders.
  • The largest ImmunityBio buyer in Q4 2018 was Renaissance Technologies, an estimated $862K added.
  • The largest ImmunityBio seller in Q4 2018 was Capital Research Global Investors, an estimated $9.85M sold.

Based on aggregated 13F filings for Q4 2018.